Clinical Trial Update: Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment [Phase 1]

View source ↗

Summary

Open-label Phase 1 pharmacokinetic study of SAR302503 in subjects with hepatic impairment; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Diseases

Drugs mentioned

• SAR302503

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatic Impairment | Phase 1 | Status: COMPLETED